Publications by authors named "Richard A Rode"

Claim this Profile
S
Sequential antiretroviral adherence measurement using electronic bottle cap monitors in a cohort of HIV-infected adults.
Jonathan Shuter, Julie A Sarlo, Roxann O Stubbs, Richard A Rode, Barry S Zingman

J Int Assoc Physicians AIDS Care (Chic)· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
W Philip T James, Ian D Caterson, Walmir Coutinho, Nick Finer, Luc F Van Gaal, Richard A Rode

N Engl J Med· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period.
Peter Weeke, Charlotte Andersson, Emil L Fosbøl, Bente Brendorp, Lars Køber, Richard A Rode

BMC Endocr Disord· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.
Jonathan Shuter, Julie A Sarlo, Richard A Rode, Barry S Zingman

HIV Clin Trials· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial.
Charlotte Andersson, Peter Weeke, Bente Brendorp, Lars Køber, Emil L Fosbøl, Richard A Rode

Nutr Metab (Lond)· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lopinavir/ritonavir in pregnancy.
Susan S Roberts, Marisol Martinez, Deborah L Covington, Richard A Rode, Mary V Pasley

J Acquir Immune Defic Syndr· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Charlotte Andersson, Peter Weeke, Emil Loldrup Fosbøl, Bente Brendorp, Lars Køber, Richard A Rode

Metabolism· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of HIV-1 genotypic resistance test interpretation algorithms.
Soo-Yon Rhee, W Jeffrey Fessel, Tommy F Liu, Natalia M Marlowe, Charles M Rowland, Richard A Rode

J Infect Dis· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.
Thomas J Podsadecki, Bernard C Vrijens, Eric P Tousset, Richard A Rode, George J Hanna

HIV Clin Trials· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
Jean-Michel Molina, Thomas J Podsadecki, Margaret A Johnson, Aimee Wilkin, Pere Domingo, Richard A Rode

AIDS Res Hum Retroviruses· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
Thomas J Podsadecki, Bernard C Vrijens, Eric P Tousset, Richard A Rode, George J Hanna

J Infect Dis· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.
Jonathan Shuter, Julie A Sarlo, Tina J Kanmaz, Richard A Rode, Barry S Zingman

J Acquir Immune Defic Syndr· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy.
Eduardo Sprinz, Andrade J Neto, Eduardo Bargman, Stephen L Green, Michelle P Luo, Richard A Rode

HIV Clin Trials· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
Bruce L Gilliam, Kirk M Chan-Tack, Roula B Qaqish, Richard A Rode, Lori E Fantry

AIDS Patient Care STDS· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
Grace P S Kwong, Azra C Ghani, Richard A Rode, Lucy M Bartley, Benjamin J Cowling

AIDS· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
Xavier Sáez-Llorens, Avyi Violari, Carl O Deetz, Richard A Rode, Perry Gomez

Pediatr Infect Dis J· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis